CN102526109A - Method for extracting composite cell multiplication factors from placenta hominis - Google Patents
Method for extracting composite cell multiplication factors from placenta hominis Download PDFInfo
- Publication number
- CN102526109A CN102526109A CN2011104580642A CN201110458064A CN102526109A CN 102526109 A CN102526109 A CN 102526109A CN 2011104580642 A CN2011104580642 A CN 2011104580642A CN 201110458064 A CN201110458064 A CN 201110458064A CN 102526109 A CN102526109 A CN 102526109A
- Authority
- CN
- China
- Prior art keywords
- extracting
- placenta hominis
- increment factor
- compound cells
- cells increment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a method for extracting composite cell multiplication factors from placenta hominis. The method comprises the following steps of: (1) cleaning and slicing the placenta hominis; (2) soaking the sliced placenta hominis with purified water, and extracting for three times to obtain an extracting solution; (3) filtering and clearing the extracting solution to obtain a clear solution; (4) firstly intercepting active substances in the clear solution through a semi-permeable membrane, and reserving permeated substances; and (5) intercepting the permeated substances for the second time through the membrane so as to obtain residues, namely composite cell multiplication factor products. Compared with the prior art, the method provided by the invention has the advantages of high product yield and the like.
Description
Technical field
The invention belongs to the health food technology field, especially relate to a kind of method of from Placenta Hominis, extracting the compound cells increment factor.
Background technology
Placenta Hominis has another name called plancenta hominis, afterbirth, Placenta Hominis, afterbirth.Be the dry Placenta Hominis that stays after the healthy women production.Placenta Hominis has the kidney warming and mends essence, the effect of benefiting QI and nourishing blood.Be mainly used in the asthenia weakness and emaciation, hectic fever due to YIN-deficiency night sweat, asthma, lack of appetite is breathed hard, impotence and seminal emission, cards such as infertile hypogalactia.These article are the antasthenic that uses clinically, resistance that can enhances human body.Informal dress Placenta Hominis powder, or fresh Placenta Hominis cooks, and can control weakness.
Along with the research of modern medicine shows, contain a large amount of active substances in the Placenta Hominis, clinically show that it is to the human body diseases treatment and will resist health care that peculiar curative effect is arranged.Just because of this, the plain product of Placenta Hominis that American-European many countries all are correlated with at active development, such as: Switzerland, France, Germany, Italy, Japan, the U.S. etc.
In existing like product, mostly exist following problem:
(1) extraction and purifying process mostly use enzyme, acid-base class, organic solvent analog assistant.The existence of these auxiliary agents can make at first that the effect material is destroyed degraded in the Placenta Hominis; In addition, the residual Product Safety that also makes of these auxiliary agents produces query.
(2) mostly there is hormone residues in product, uses people from back that known from experience and has side effects.
(3) mostly the functional component of all product in market is protein, polypeptide and the aminoacid after the degraded, and it is the supplement nutritional products of higher gears at most, and has lost the bioactive substance that is contained in the original Placenta Hominis.
Summary of the invention
The object of the invention is exactly the method for from Placenta Hominis, extracting the compound cells increment factor that a kind of effect of high product significantly is provided for the defective that overcomes above-mentioned prior art existence.
The object of the invention can be realized through following technical scheme: a kind of method of from Placenta Hominis, extracting the compound cells increment factor is characterized in that this method may further comprise the steps:
(1) Placenta Hominis is cleaned up section;
(2) with the Placenta Hominis of section with pure water soaking and extracting 3 times, obtain extracting solution;
(3) after the extracting liquid filtering clarification, get clear liquid;
(4) clear liquid is at first carried out active substance through semipermeable membrane and dam, will appear thing and keep;
(5) will appear thing and carry out damming the second time through film, the gained residue is compound cells increment factor product.
The described pure water soaking and extracting of step (2) is specially for 3 times: Placenta Hominis was mixed stirring with pure water by weight 1: 16, and mixing speed 20-30rmp, the time is 2 hours, filters, and gained filtrating is extracting solution, and filtering residue is circulation extraction once more, extracts altogether three times.
The described extracting liquid filtering clarification of step (3) is: extracting solution is crossed 200 mesh sieves, after the filtration, filtrating is left standstill 12h, extracting the supernatant out is to carry out high speed centrifugation under the 8000-10000rpm at rotating speed, gets clear liquor.
The molecular weight of the described semipermeable membrane of step (4) is 100k.
The molecular weight of the described film of step (5) is 5k.
Step (5) gained compound cells increment factor product can directly be processed injection according to drug formulation, or carries out processing oral formulations after the lyophilization.
Compared with prior art, the present invention extracts purification according to the size of compound cells MF molecular weight contained in the Placenta Hominis, has developed the product with excellent activity, processes injection or oral formulations, and effect is high.
The specific embodiment
Below in conjunction with specific embodiment the present invention is elaborated.
Embodiment 1
A kind of method of from Placenta Hominis, extracting the compound cells increment factor is characterized in that this method may further comprise the steps:
(1) Placenta Hominis is cleaned up section;
(2) with the Placenta Hominis of section with pure water soaking and extracting 3 times, obtain extracting solution;
(3) after the extracting liquid filtering clarification, get clear liquid;
(4) clear liquid is at first carried out active substance through semipermeable membrane and dam, will appear thing and keep;
(5) will appear thing and carry out damming the second time through film, the gained residue is compound cells increment factor product.
Gained compound cells increment factor product can directly be processed injection according to drug formulation, or carries out processing oral formulations after the lyophilization.
Product of the present invention is analyzed as follows:
Product of the present invention is used for clinical research:
Carried out clinical double-blind trial to chronic hepatitis and liver cirrhosis patient 96 people, confirmed that the utilization of this product has obviously improved patients serum's transaminase (GOT, GPT) value, its obvious effective rate has reached more than 90%.
Embodiment 2
A kind of method of from Placenta Hominis, extracting the compound cells increment factor is characterized in that this method may further comprise the steps:
(1) Placenta Hominis is cleaned up section;
(2) Placenta Hominis with section mixed stirring with pure water by weight 1: 16, mixing speed 20-30rmp, and the time is 2 hours, filters, and gained filtrating is extracting solution, and filtering residue is circulation extraction once more, extracts altogether three times, obtains extracting solution;
(3) carried 200 mesh sieves, and after the filtration, filtrating was left standstill 12h, extracting the supernatant out is to carry out high speed centrifugation under the 8000-10000rpm at rotating speed, gets clear liquor;
(4) be that the semipermeable membrane of 100k carries out active substance and dams at first with clear liquor, will appear thing and keep through molecular weight;
(5) will appear thing is that the film of 5k carries out damming the second time through molecular weight, and the gained residue is compound cells increment factor product.
Gained compound cells increment factor product can directly be processed injection according to drug formulation, or carries out processing oral formulations after the lyophilization.
Claims (6)
1. method of from Placenta Hominis, extracting the compound cells increment factor is characterized in that this method may further comprise the steps:
(1) Placenta Hominis is cleaned up section;
(2) with the Placenta Hominis of section with pure water soaking and extracting 3 times, obtain extracting solution;
(3) after the extracting liquid filtering clarification, get clear liquid;
(4) clear liquid is at first carried out active substance through semipermeable membrane and dam, will appear thing and keep;
(5) will appear thing and carry out damming the second time through film, the gained residue is compound cells increment factor product.
2. a kind of method of from Placenta Hominis, extracting the compound cells increment factor according to claim 1 is characterized in that the described pure water soaking and extracting of step (2) is specially for 3 times: Placenta Hominis was mixed stirring with pure water by weight 1: 16; Mixing speed 20-30rmp; Time is 2 hours, filters, and gained filtrating is extracting solution; Filtering residue is circulation extraction once more, extracts altogether three times.
3. a kind of method of from Placenta Hominis, extracting the compound cells increment factor according to claim 1; It is characterized in that; The described extracting liquid filtering clarification of step (3) is: extracting solution is crossed 200 mesh sieves, after the filtration, filtrating is left standstill 12h; Extracting the supernatant out is to carry out high speed centrifugation under the 8000-10000rpm at rotating speed, gets clear liquor.
4. a kind of method of from Placenta Hominis, extracting the compound cells increment factor according to claim 1 is characterized in that the molecular weight of the described semipermeable membrane of step (4) is 100k.
5. a kind of method of from Placenta Hominis, extracting the compound cells increment factor according to claim 1 is characterized in that the molecular weight of the described film of step (5) is 5k.
6. a kind of method of from Placenta Hominis, extracting the compound cells increment factor according to claim 1; It is characterized in that; Step (5) gained compound cells increment factor product can directly be processed injection according to drug formulation, or carries out processing oral formulations after the lyophilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104580642A CN102526109A (en) | 2011-12-31 | 2011-12-31 | Method for extracting composite cell multiplication factors from placenta hominis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104580642A CN102526109A (en) | 2011-12-31 | 2011-12-31 | Method for extracting composite cell multiplication factors from placenta hominis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102526109A true CN102526109A (en) | 2012-07-04 |
Family
ID=46334931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104580642A Pending CN102526109A (en) | 2011-12-31 | 2011-12-31 | Method for extracting composite cell multiplication factors from placenta hominis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526109A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040616A (en) * | 2006-03-24 | 2007-09-26 | 珠海亿胜生物制药有限公司 | Pharmaceutical amniotic membrane and processes for their prepn. |
| CN101199837A (en) * | 2007-11-30 | 2008-06-18 | 何荫良 | Humanized cell factor hair agent and preparing method thereof |
| CN101380333A (en) * | 2008-09-25 | 2009-03-11 | 浙江金时代生物技术有限公司 | Method for extracting cellular fluid from human homogeneous variant cell |
| CN101380332A (en) * | 2008-09-25 | 2009-03-11 | 浙江金时代生物技术有限公司 | Human homogeneous variant cell extract and use thereof |
-
2011
- 2011-12-31 CN CN2011104580642A patent/CN102526109A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040616A (en) * | 2006-03-24 | 2007-09-26 | 珠海亿胜生物制药有限公司 | Pharmaceutical amniotic membrane and processes for their prepn. |
| CN101199837A (en) * | 2007-11-30 | 2008-06-18 | 何荫良 | Humanized cell factor hair agent and preparing method thereof |
| CN101380333A (en) * | 2008-09-25 | 2009-03-11 | 浙江金时代生物技术有限公司 | Method for extracting cellular fluid from human homogeneous variant cell |
| CN101380332A (en) * | 2008-09-25 | 2009-03-11 | 浙江金时代生物技术有限公司 | Human homogeneous variant cell extract and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100446779C (en) | Method for preparing acanthopanax senticousus extracting liquid/extraction | |
| CN101037468A (en) | Preparation method of oyster active peptides | |
| CN102030834A (en) | Method for extracting and preparing camellia polysaccharide from camellia and application of camellia polysaccharide | |
| CN104523547A (en) | Preparation process research of andrias davidianus blanchard facial mask and application method of andrias davidianus blanchard facial mask | |
| CN104284601A (en) | Pleuropterus multiflorus extract and dipsacus asperoides extract for secreting insulin-like growth factor and promoting bone structure growth, and method for preparing same | |
| CN101524167A (en) | Small-molecule sea cucumber powder and small-molecule sea cucumber powder capsules | |
| CN104306401B (en) | A kind of preparation of the sika deer deer spleen extract of function of increasing leukocyte and purposes | |
| CN102526109A (en) | Method for extracting composite cell multiplication factors from placenta hominis | |
| CN103251908B (en) | Hair-restorer and preparation method thereof | |
| CN105646656B (en) | Griseus shark cartilage protein antioxidant peptide and application thereof | |
| CN105132503B (en) | Stone tortoise active peptide method for refining and prevention cirrhosis, it is antifatigue in application | |
| CN110559327B (en) | Liver-protecting product and preparation method thereof | |
| CN103805663A (en) | Method for separating, purifying and extracting bioactive peptide from marine product | |
| CN103611023A (en) | Preparation method of transfer factor | |
| CN1053104C (en) | Anti-decrepitude, nourishing and health care oral medicine liqnid | |
| CN101357225A (en) | Preparation method of medicine for treating elderly cerebral dysfunction | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN103705907A (en) | Preparation method and application of turtle shell active polypeptide extractive | |
| CN103907810A (en) | Five-red-component preparation and preparation method thereof | |
| CN105646658B (en) | Ray porosa chondroprotein antioxidant peptide and application thereof | |
| CN101703233A (en) | Ginkgo Chinese caterpillar fungus polysaccharide capsule and preparation method thereof | |
| CN105420330B (en) | Preparation method of raja porosa chondroprotein antioxidant peptide | |
| CN102475760B (en) | Kidney-health compound preparation for treating chronic renal failure and preparation method thereof | |
| CN106106953A (en) | Radix Et Rhizoma Fagopyri Tatarici polypeptide tea and preparation method thereof | |
| CN105648007A (en) | Preparation method of mustelus griseus chondroprotein antioxidative peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120704 |